The road to tolerance: Renal transplant tolerance induction in nonhuman primate studies and clinical trials

Transplant Immunology

Volumn 13, Issue 2, 2004, Pages 87-99

  Elster, Eric A ^a,b,c   Hale, Douglas A ^a,c   Mannon, Roslyn B ^a   Cendales, Linda C ^a   Swanson, S John ^a,c   Kirk, Allan D ^a,c,d  

^a Laboratory of Neuroscience   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d Building 10 Center Drive ^*  (United States)

Author keywords

Costimulation blockade; Lymphocyte depletion; Mixed chimerism; Tolerance

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CD80 MONOLONAL ANTIBODY; CD86 MONOLONAL ANTIBODY; COLECALCIFEROL; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; HEPARIN; HU 5C8; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 10; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOIMMUNITY; CHIMERA; CLINICAL TRIAL; CLONAL ANERGY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE;

EID: 4544248633     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2004.05.010     Document Type: Article

References (86)

1. 2002 Annual Report: the U.S. Organ Procurement and Transplantation Network and The Scientific Registry of Transplant Recipients. United Network for Organ Sharing; 2002.
2. Hariharan S., et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. 342:2000;605-612
3. Tanphaichitr N.T., Brennan D.C. Infectious complications in renal transplant recipients. Adv. Ren. Replace. Ther. 7:2000;131-146
4. Penn I. Cancers in renal transplant recipients. Adv. Ren. Replace. Ther. 7:2000;147-156
5. Schwenger V., Zeier M., Ritz E. Hypertension after renal transplantation. Ann. Transplant. 6:2001;25-30
6. Pannu H.S., Singh D., Sandhu J.S. Lipid profile before and after renal transplantation - a longitudinal study. Ren. Fail. 25:2003;411-417
7. Sprague S.M., Josephson M.A. Bone disease after kidney transplantation. Semin. Nephrol. 24:2004;82-90
8. Pilmore H.L., Dittmer I.D. Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin. Transplant. 16:2002;191-195
9. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., Chapman J.R. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349:2003;2326-2333
10. Kirk A.D. Transplantation tolerance: a look at the nonhuman primate literature in the light of modern tolerance theories. Crit. Rev. Immunol. 19:1999;349-388
11. Kirk A.D., Harlan D.M. Challenges for the clinical application of transplant tolerance strategies. Curr. Opin. Organ Transpl. 5:2000;108-113
12. Bluestone J.A., Matthews J.B., Krensky A.M. The immune tolerance network: the "Holy Grail" comes to the clinic. J. Am. Soc. Nephrol. 11:2000;2141
13. Preston E., Kirk A.D. Context-based therapy: a conceptual framework for transplantation tolerance. Transplant. Rev. 16:2002;142-162
14. Matzinger P. An innate sense of danger. Semin. Immunol. 10:1998;399
15. Matzinger P. An innate sense of danger. Ann. N. Y. Acad. Sci. 961:2002;341
16. Medzhitov R., Janeway C. Jr. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173:2000;89
17. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science. 272:1996;50
18. Pratt J.R., Basheer S.A., Sacks S.H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat. Med. 8:2002;582
19. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5:1999;1249
20. Kirk A.D. Let's blame the little guys: platelets as an instigator of allograft rejection? Graft. 2:1999;159-160
21. Kirk A.D., Blair P.J., Tadaki D.K., Xu H., Harlan D.M. The role of CD154 in organ transplant rejection and acceptance. Philos. Trans. R Soc. Lond. B Biol. Sci. 356:2001;691
22. Czapiga M., Kirk A.D., Lekstrom-Himes J. Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. Exp. Hematol. Exp. Hematol. 32:2004;135-139
23. Larsen C.P., Morris P.J., Austyn J.M. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J. Exp. Med. 171:1990;307-314
24. Zinkernagel R.M. Localization dose and time of antigens determine immune reactivity. Semin. Immunol. 12:2000;163-171
25. Harlan D.M., Kirk A.D. The future of organ and tissue transplantation: is a new paradigm on the horizon? J. Amer. Med. Assoc. 282:1999;1076-1082
26. Lakkis F.G., Sayegh M.H. Memory T cells: a hurdle to immunologic tolerance. J. Am. Soc. Nephrol. 14:2003;2402-2410
27. Adams A.B., Pearson T.C., Larsen C.P. Heterologous immunity: an overlooked barrier to tolerance. Immunol. Rev. 196:2003;147
28. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3:1995;541-547
29. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 27:2001;68-73
30. Noel P.J., Boise L.H., Thompson C.B. Regulation of T cell activation by CD28 and CTLA4. Adv. Exp. Med. Biol. 406:1996;209-217
31. Mackey M.F., Barth R.J. Jr., Noelle R.J. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J. Leukoc. Biol. 63:1998;418
32. van Kooten C., Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9:1997;330
33. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3:2003;199-210
34. Waldmann H., Graca L., Cobbold S., Adams E., Tone M., Tone Y. Regulatory T cells and organ transplantation. Semin Immunol. 16:2004;119-126
35. Jiang S., Lechler R.I. Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transplant. 3:2003;516-524
36. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3:2002;135-142
37. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198:2003;1875-1886
38. Sykes M., Sachs D.H. Mixed chimerism. Philos. Trans. R Soc. Lond. B Biol. Sci. 356:2001;707-726
39. Salama A.D., Remuzzi G., Harmon W.E., Sayegh M.H. Challenges to achieving clinical transplantation tolerance. J. Clin. Invest. 108:2001;943
40. Buhler L.H., Spitzer T.R., Sykes M., et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation. 74:2002;1405
41. Kawai T., Sachs D.H., Cosimi A.B. Tolerance to vascularized organ allografts in large-animal models. Curr. Opin. Immunol. 11:1999;516-520
42. Wells A.D., Li X.C., Strom T.B., Turka L.A. The role of peripheral T-cell deletion in transplantation tolerance. Philos. Trans. R Soc. Lond. B Biol. Sci. 356:2001;617-623
43. Kirk A.D. Crossing the bridge: large animal models in translational transplantation research. Immunol. Rev. 196:2003;176
44. Larsen C.P., Elwood E.T., Alexander D.Z., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 381:1996;434
45. Kirk A.D., Harlan D.M., Armstrong N.N., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U. S. A. 94:1997;8789
46. Kirk A.D., Burkly L.C., Batty D.S., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5:1999;686
47. Xu H., Elster E., Batty D., et al. Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. Transplant Proc. 33:2001;223
48. Elster E.A., Xu H., Tadaki D.K., et al. Primate skin allotransplantation with anti-CD154 monotherapy. Transplant Proc. 33:2001;675
49. Elster E.A., Xu H., Tadaki D.K., et al. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation. 72:2001;1473
50. Xu H., Elster E.A., Blair P.J., et al. Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. Am. J. Transplant. 3:2003;1350
51. Pearson T.C., Trambley J., Odom K., et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation. 74:2002;933
52. Montgomery S.P., Xu H., Tadaki D.K., et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 74:2002;1365
53. Kirk A.D., Tadaki D.K., Celniker A., Batty D.S., Berning J.D., Colonna J.O., et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation. 72:2001;377-384
54. Adams A.B., Shirasugi N., Durham M.M., Strobert E., Anderson D., Rees P., et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes. 51:2002;265-270
55. Knechtle S.J., Fechner J.H. Jr., Dong Y., et al. Primate renal transplants using immunotoxin. Surgery. 124:1998;438
56. Armstrong N., Buckley P., Oberley T., et al. Analysis of primate renal allografts after T-cell depletion with anti-CD3-CRM9. Transplantation. 66:1998;5
57. Knechtle S.J., Vargo D., Fechner J., et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation. 63:1997;1
58. Hutchings A., Wu J., Asiedu C., et al. The immune decision toward allograft tolerance in non-human primates requires early inhibition of innate immunity and induction of immune regulation. Transpl. Immunol. 11:2003;335
59. Montgomery S., Hale D.A., Hirschberg B., Harlan D.M., Kirk A.D. Preclinical evaluation of tolerance induction protocols and islet transplantation in non-human primates. Immunological. Rev. 183:2002;214-222
60. Myburgh J.A., Smit J.A., Mieny C.J., Mason J.A. Hepatic allotransplantation in the baboon: 3. The effects of immunosuppression and administration of donor-specific antigen after transplantation. Transplantation. 12:1971;202
61. Kawai T., Poncelet A., Sachs D.H., et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation. 68:1999;1767
62. Kawai T., Abrahamian G., Sogawa H., et al. Costimulatory blockade for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. Transplant Proc. 33:2001;221
63. Kirk A.D. Ethics in the quest for transplant tolerance. Transplantation. 77:2004;947-951
64. Kirk A.D., Knechtle S.J., Sollinger H., Vincenti F.G., Stecher S., Nadeau K. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am. J. Transplant. 1:2001;S191
65. Kirk A.D., Harlan D.M. Reply: increased incidence of thromboembolic complications following anti-CD40L monoclonal antibody treatment in cynomolgus monkeys. Letter to the Editor. Nat. Med. 6:2000;114
66. http://www.immunetolerance.org/eXpress/research/2003-1/vincenti.html. Immune Tolerance Network Newsletter, Vol. 1 Number 1, July 2003 Accessed 2003.
67. Calne R., Friend P., Moffatt S., et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 351:1998;1701
68. Kirk A.D., Hale D.A., Mannon R.B., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 76:2003;120
69. Calne R., Moffatt S.D., Friend P.J., et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 68:1999;1613-1616
70. Kirk A. Results from a human tolerance trial using alemtuzumab (campath-1H) with deoxyspergualin (DSG). Am. J. Transplant. 3(S5):2003;S310
71. Swanson S.J., Hale D.A., Mannon R.B., et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet. 360:2002;1662
72. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5:1999;1298
73. Knechtle S.J., Pirsch J.D., Fechner H.J.J., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. 3:2003;722
74. Leventhal J.R., Gallon L., Kaufman D.B., et al. Alemtuzumab (Campath 1-H) facilitates prednisone-free immunosuppression (IP) in kidney transplant recipients. Am. J. Transplant. 3(Suppl 5):2003;310
75. Shapiro R., Jordan M.L., Basu A., et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann. Surg. 238:2003;520
76. Spitzer T.R., Delmonico F., Tolkoff-Rubin N., et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation. 68:1999;480
77. Spitzer T.R. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist. 5:2000;215
78. Strober S., Benike C., Krishnaswamy S., Engleman E.G., Grumet F.C. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation. 69:2000;1549
79. Millan M.T., Shizuru J.A., Hoffmann P., et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation. 73:2002;1386
80. Spitzer T.R., McAfee S., Sackstein R., et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol. Blood Marrow Transplant. 6:2000;309
81. Trivedi H.L., Shah V.R., Vanikar A.V., et al. High-dose peripheral blood stem cell infusion: a strategy to induce donor-specific hyporesponsiveness to allografts in pediatric renal transplant recipients. Pediatr. Transplant. 6:2002;63
82. Chase M.W. Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc. Soc. Exp. Biol. Med. 61:1946;257-259
83. Sulzberger M.B. Hypersensitiveness to neoarsphenamine in guinea-pigs: experiments in prevention and in desensitization. Arch. Derm. Syph. 20:1929;669-681
84. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., Turka L.A. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166:2001;973
85. Heeger P.S. T-cell allorecognition and transplant rejection: a summary and update. Am. J. Transplant. 3:2003;525
86. Hoffmann S.C., Pearl J.P., Blair P.J., Kirk A.D. Immune profiling: molecular monitoring in renal transplantation. Front Biosci. 8:2003;e444